<Suppliers Price>

Rat CGRP-(8-37)

Names

[ CAS No. ]:
129121-73-9

[ Name ]:
Rat CGRP-(8-37)

[Synonym ]:
h-val-thr-his-arg-leu-ala-gly-leu-leu-ser-arg-ser-gly-gly-val-val-lys-asp-asn-phe-val-pro-thr-asn-val-gly-ser-glu-ala-phe-nh2
val-thr-his-arg-leu-ala-gly-leu-leu-ser-arg-ser-gly-gly-val-val-lys-asp-asn-phe-val-pro-thr-asn-val-gly-ser-glu-ala-phe-nh2
vthrlagllsrsggvvkdnfvptnvgseaf-nh2
Rat CGRP-(8-37)

Biological Activity

[Description]:

Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective CGRP receptor antagonist.

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> CGRP Receptor
Signaling Pathways >> Neuronal Signaling >> CGRP Receptor
Research Areas >> Cardiovascular Disease
Research Areas >> Neurological Disease
Peptides

[Target]

CGRP receptor[1]


[In Vitro]

CGRP-(8-37) is a truncated version of calcitonin gene-related peptide (CGRP) that binds to the CGRP receptor with similar affinity but does not activate the receptor[1].

[In Vivo]

CGRP-(8-37) is effective in alleviating mechanical and thermal allodynia in a dose-dependent manner. The 50 nM dose is most efficacious for both forelimb and hindlimb responses. The period of efficacy is 10 min to onset for a duration of 20 min. Post-drug washout responses are not statistically significant compared to pre-drug responses[1]. Intrathecal administration of 5 nmol or 10 nmol of CGRP-(8-37), but not 1 nmol, induces a significant increase in hindpaw withdrawal latency. Intrathecal administration of CGRP-(8-37) not only reverses the SP-induced decrease in latency to both withdrawal responses but also mediates a significant increase in response latency compared to basal levels[2].

[Animal admin]

Rats: Adult male Sprague Dawley rats are given a spinal hemisection or a sham surgery at the T13 spinal segment. An externally accessible PE-10 intrathecal catheter that terminated at T13 is used for drug delivery. Animals are allowed to recover for 4 weeks at which time the hemisected animals displayed mechanical and thermal allodynia bilaterally, in both forelimbs and hindlimbs. CGRP-(8-37) is delivered just prior to a testing session in 1, 5, 10, or 50 nM doses in artificial cerebral spinal fluid in 10 mL volumes[1].

[References]

[1]. Bennett AD, et al. Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chroniccentral pain. Pain. 2000 May;86(1-2):163-75.

[2]. Yu LC, et al. The calcitonin gene-related peptide antagonist CGRP8-37 increases the latency to withdrawalresponses in rats. Brain Res. 1994 Aug 8;653(1-2):223-30.


[Related Small Molecules]

Olcegepant | BMS-927711 | MK-0974 | MK-3207 HCl | Calcitonin Gene Related Peptide Fragment 8-37 human | Adrenomedullin (22-52) (human) | Ubrogepant | β-CGRP (human)

Chemical & Physical Properties

[ Molecular Formula ]:
C138H224N42O41

[ Molecular Weight ]:
3127.51000

[ Exact Mass ]:
3125.67000

[ PSA ]:
1344.65000

[ LogP ]:
0.05010

[ Storage condition ]:
-20°C


Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.